HomeCompareSGEN vs ADC

SGEN vs ADC: Dividend Comparison 2026

SGEN yields 0.87% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $158.0K in total portfolio value
10 years
SGEN
SGEN
● Live price
0.87%
Share price
$228.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$92.54
Full SGEN calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — SGEN vs ADC

📍 ADC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGENADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGEN + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGEN pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGEN
Annual income on $10K today (after 15% tax)
$74.32/yr
After 10yr DRIP, annual income (after tax)
$78.66/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,599.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGEN + ADC for your $10,000?

SGEN: 50%ADC: 50%
100% ADC50/50100% SGEN
Portfolio after 10yr
$99.9K
Annual income
$40,444.92/yr
Blended yield
40.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

SGEN
Analyst Ratings
14
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$171.82
-24.9% upside vs current
Range: $120.00 — $222.00
Altman Z
23.3
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGEN buys
0
ADC buys
0
No recent congressional trades found for SGEN or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGENADC
Forward yield0.87%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$20.9K$178.9K
Annual income after 10y$92.54$80,797.29
Total dividends collected$902.00$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$171.82$81.06

Year-by-year: SGEN vs ADC ($10,000, DRIP)

YearSGEN PortfolioSGEN Income/yrADC PortfolioADC Income/yrGap
1← crossover$10,787$87.44$10,990$580.36$203.00ADC
2$11,631$88.15$12,301$860.26$670.00ADC
3$12,534$88.82$14,104$1,298.62$1.6KADC
4$13,500$89.46$16,691$2,008.16$3.2KADC
5$14,536$90.05$20,580$3,205.09$6.0KADC
6$15,644$90.62$26,754$5,330.02$11.1KADC
7$16,830$91.14$37,196$9,345.14$20.4KADC
8$18,100$91.64$56,244$17,523.09$38.1KADC
9$19,459$92.11$94,286$35,736.21$74.8KADC
10$20,913$92.54$178,949$80,797.29$158.0KADC

SGEN vs ADC: Complete Analysis 2026

SGENStock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Full SGEN Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this SGEN vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGEN vs SCHDSGEN vs JEPISGEN vs OSGEN vs KOSGEN vs MAINSGEN vs NNNSGEN vs EPRTSGEN vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.